Inventiva S.A. (IVA)

NASDAQ: IVA · IEX Real-Time Price · USD
2.670
-0.300 (-10.10%)
At close: Jun 17, 2024, 4:00 PM
2.700
+0.030 (1.12%)
Pre-market: Jun 18, 2024, 6:09 AM EDT
-10.10%
Market Cap 139.83M
Revenue (ttm) 25.74M
Net Income (ttm) -122.70M
Shares Out 52.37M
EPS (ttm) -2.60
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 9,273
Open 2.900
Previous Close 2.970
Day's Range 2.670 - 2.970
52-Week Range 2.670 - 4.870
Beta 0.97
Analysts Strong Buy
Price Target 18.00 (+574.16%)
Earnings Date Jun 25, 2024

About IVA

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, Fra... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jul 10, 2020
Employees 120
Stock Exchange NASDAQ
Ticker Symbol IVA
Full Company Profile

Financial Performance

In 2023, Inventiva's revenue was 23.16 million, an increase of 23.12% compared to the previous year's 18.81 million. Losses were -110.43 million, 103.5% more than in 2022.

Financial numbers in EUR Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for IVA stock is "Strong Buy." The 12-month stock price forecast is $18.0, which is an increase of 574.16% from the latest price.

Price Target
$18.0
(574.16% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Combined General Meeting of June 20, 2024 - Availability of the preparatory documents

Daix (France), Long Island City (New York, United States), May 30, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral smal...

19 days ago - GlobeNewsWire

Inventiva announces two scientific presentations at the EASL International Liver Congress™ 2024

Daix (France), Long Island City (New York, United States), May 22, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral smal...

26 days ago - GlobeNewsWire

Inventiva reports 2024 First Quarter Financial Information¹ and provides a corporate update

Daix (France), Long Island City (New York, United States), May 21, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the developm...

27 days ago - GlobeNewsWire

Inventiva announces the positive recommendation of the fourth DMC of the NATiV3 Phase III clinical trial with lanifibranor in patients with MASH/NASH

Daix (France), Long Island City (New York, United States), May 16, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the developm...

4 weeks ago - GlobeNewsWire

Inventiva announces the publication in Nature Communications of additional results from NATIVE Phase IIb clinical trial demonstrating improvement of markers of cardiometabolic health in patients with MASH/NASH treated with lanifibranor

Daix (France), Long Island City (New York, United States), May 13, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral smal...

5 weeks ago - GlobeNewsWire

Inventiva announces filing of its 2023 Universal Registration Document and 2023 Annual Report on Form 20-F

Daix (France), Long Island City (New York, United States), April 3, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the develop...

2 months ago - GlobeNewsWire

Inventiva announces the nomination of Andre Turenne as Director

Daix (France), Long Island City (New York, United States), March 28, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the develo...

2 months ago - GlobeNewsWire

Inventiva reports its 2023 full-year results

Revenues at €17.5 million for the full year of 2023 up 43.4% compared to €12.2 million for 2022  Cash and cash equivalents at €26.9 million, short-term deposits at €0.01 million1, and long-term deposi...

2 months ago - GlobeNewsWire

Inventiva announces the schedule of publication and presentation of its 2023 Full-Year Financial Results

Daix (France), Long Island City (New York, United States), March 22, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral sm...

3 months ago - GlobeNewsWire

Inventiva announces positive results from the Phase II, LEGEND, Proof-of-Concept study combining lanifibranor with empagliflozin in patients with MASH/NASH and T2D

Daix (France), Long Island City (New York, United States), March 18, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral sm...

3 months ago - GlobeNewsWire

Inventiva to present the results of LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and T2D

Daix (France), Long Island City (New York, United States), March 13, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the develo...

3 months ago - GlobeNewsWire

Inventiva announces that screening in the NATiV3, Phase III, clinical trial evaluating lanifibranor in NASH has resumed

Daix (France), Long Island City (New York, United States), March 7, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the develop...

3 months ago - GlobeNewsWire

Inventiva reports preliminary 2023 fiscal year financial Information¹ and provides an update on its clinical trial NATiV3

Daix (France), Long Island City (New York, United States), February 15, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the dev...

4 months ago - GlobeNewsWire

Half-Year Review of Inventiva's Liquidity Contract with Kepler Cheuvreux

Daix (France), Long Island City (New York, United States), January 24, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the deve...

5 months ago - GlobeNewsWire

Inventiva draws down the second tranche of €25 million under existing Finance Contract with the European Investment Bank

Daix (France), Long Island City (New York, United States), January 10, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the deve...

5 months ago - GlobeNewsWire

Inventiva announces the randomization of the first patient in China in the NATiV3 clinical trial and provides an update on its clinical development program

The first patient was randomized in China in the NATiV3 Phase III clinical trial, triggering a milestone payment of $3 million from CTTQ to Inventiva.  With this milestone payment Inventiva expects to...

6 months ago - GlobeNewsWire

Inventiva announces the positive recommendation of the third DMC of the Phase III clinical trial with lanifibranor in patients with NASH

Daix (France), Long Island City (New York, United States), December 4, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the deve...

7 months ago - GlobeNewsWire

Inventiva reports 2023 Third Quarter Financial Information¹

Daix (France), Long Island City (New York, United States), November 21, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the dev...

7 months ago - GlobeNewsWire

Inventiva announces a late breaker abstract and two additional abstracts on its lead compound, lanifibranor, at the AASLD The Liver Meeting® 2023

Daix (France), Long Island City (New York, United States), November 6, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the deve...

8 months ago - GlobeNewsWire

Inventiva reports its 2023 first-half financial results and provides a corporate update

Daix (France), Long Island City (New York, United States), September 28, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the de...

9 months ago - GlobeNewsWire

Inventiva and Hepalys Pharma, Inc. announce exclusive licensing agreement to develop and commercialize lanifibranor in Japan and South Korea

Hepalys Pharma, Inc. is a new company created by Catalys Pacific and in which Inventiva has a 30% ownership position.   Under the exclusive licensing agreement, Inventiva will receive a $10 million up...

9 months ago - GlobeNewsWire

Inventiva announces a financing of approximately €35.7 million from new and existing investors, consisting of a €30.6 million reserved capital increase and a €5.1 million issuance of royalty certificates

Daix (France), Long Island City (New York, United States), August 31, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the devel...

10 months ago - GlobeNewsWire

Correction: Inventiva Reports Preliminary 2023 First-Half Financial Information¹ and Business update

Cash and cash equivalents at €31.2 million, short-term deposits at €0.05 million2, and long-term deposit at €9.3 million3 as of June 30, 2023, compared to €86.7 million, €1.0 million and €0.7 million ...

11 months ago - GlobeNewsWire

Inventiva Reports Preliminary 2023 First-Half Financial Information¹ and Business update

Cash and cash equivalents at €31.2 million, short-term deposits at €0.05 million2, and long-term deposit at €9.3 million3 as of June 30, 2023, compared to €86.7 million, €1.0 million and €0.7 million ...

11 months ago - GlobeNewsWire

Inventiva announces the presentation of a scientific abstract at the 83rd Scientific Sessions of the American Diabetes Association

Daix (France), Long Island City (New York, United States) , June 2 4 , 2023 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral ...

1 year ago - GlobeNewsWire